GSK.L

Equity

GSK PLC ORD 31 1/4P

Health Care · Drug Manufacturers - General

$2,201.00

+2,201.00 (+0.00%)

Open

N/A

Day Range

$2,153.00 - $2,201.00

52W Range

$1,242.50 - $2,282.00

Volume

14M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
ABBV AbbVie Inc. $232.06 N/A 2.87% +0.00%
LLY Eli Lilly and Company $1,052.20 N/A 0.59% +0.00%
NVO Novo Nordisk A/S $37.46 N/A 4.49% +0.00%
EJG.F EBOS Group Ltd. R $11.70 N/A 5.14% +0.00%
5889.T JAPAN EYEWEAR HOLDINGS CO LTD $1,998.00 N/A 4.20% +0.00%
0332.KL TOPVISN $0.17 N/A 11.76% +0.00%
ABT Abbott Laboratories $116.32 N/A 2.06% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About GSK PLC ORD 31 1/4P

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.

www.gsk.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share